

Cross Shore Acquisition Corporation

29 August 2007

### Result of Special General Meeting

Cross Shore Acquisition Corporation (“Cross Shore”) announces that the first four resolutions proposed at its adjourned Special General Meeting held on Tuesday 28 August 2007 were duly passed. The resolutions approved, inter alia, the reverse takeover of ReSearch Pharmaceutical Services, Inc. (the “Acquisition”) and the change of the Company’s name to ReSearch Pharmaceutical Services, Inc.

The fifth resolution, which sought shareholder approval for the waiver of the requirement to obtain a determination of the value of the Exchange Shares, was not passed. Consequently, in order to satisfy the necessary condition to the Merger Agreement, the Board of Cross Shore will obtain the necessary valuation as part of the completion process.

The Acquisition, including the satisfaction of the valuation opinion condition, is expected to be completed by close of business on Thursday 30 August 2007, Eastern Standard Time.

Shareholders that elected to have an aggregate 8.4 million shares repurchased by the Company (as described in the re-admission document dated 5 June 2007), will, conditional upon completion of the Acquisition, have their shares repurchased upon receipt by the Company of original share certificates.

Subject to completion of the Acquisition, the admission to trading on AIM of Cross Shore’s existing shares and warrants will be cancelled and an application has been made for up to 42,003,422 shares and up to 2,986,667 warrants to be re-admitted to trading on AIM. The cancellation and re-admission to trading of both the shares and warrants is expected to become effective at 8.00 a.m. on 31 August 2007, as is the Company’s change of name. Until that time, trading in Cross Shore shares and warrants has been suspended with immediate effect.

Following the repurchase of shares, the cancellation of 3,000,001 Founder Shares and the completion of both the warrant tender offer and the revised Sunrise tender offer, 33,506,377 shares and 1,414,694 warrants will be in issue. It is anticipated that these steps will be completed shortly after re-admission to AIM.

In connection with the Acquisition, Pangaea One Acquisition Holdings I, LLC, an affiliate of Cartesian Capital Group, LLC, has now agreed to acquire approximately 10.7 million Cross Shore shares, including those that will result from conversion of warrants

under the warrant tender offer and including certain shares to be acquired from the Founding Shareholders. Following completion of these purchases and the steps outlined in the paragraph above, Pangaea will hold approximately 32.8% of the outstanding share capital of the Company.

From 31 August 2007, Cross Shore's shares and warrants are expected to trade under the symbols RPSE and RPSW respectively.

ENQUIRIES:

Cross Shore +1 843 597 4760  
Dennis Smith

ReSearch Pharmaceutical Services +1 215 540 0700  
Dan Perlman

Arbuthnot Securities Limited +44 207 012 2000  
Nominated Adviser and UK Broker  
James Steel / Guy Blakeney

*Arbuthnot Securities Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as nominated adviser and UK broker to the Company in connection with Re-admission. Its responsibilities as the Company's nominated adviser under the AIM Rules are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or Proposed Director or to any other person.*

*Arbuthnot Securities Limited is acting exclusively for the Company and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or the Re-admission. No representation or warranty, express or implied, is made by Arbuthnot Securities Limited as to the contents of this announcement. The information contained in this announcement is not intended to inform or be relied upon by any subsequent purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and accordingly no duty of care is accepted in relation to them.*

*The Directors and Proposed Directors of Cross Shore Acquisition Corporation accept responsibility, individually and collectively, for the information contained in this announcement and for compliance with the AIM Rules. To the best of the knowledge and belief of the Directors and Proposed Directors, who have taken all reasonable care to ensure that such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.*

END